These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 31883702)

  • 1. Rate of Adverse Events and Associated Health Care Costs for the Management of Inflammatory Bowel Disease in Germany.
    Wilke T; Groth A; Long GH; Tatro AR; Sun D
    Clin Ther; 2020 Jan; 42(1):130-143.e3. PubMed ID: 31883702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data.
    Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN
    Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
    Burisch J
    Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry.
    Bokemeyer B; Hardt J; Hüppe D; Prenzler A; Conrad S; Düffelmeyer M; Hartmann P; Hoffstadt M; Klugmann T; Schmidt C; Weismüller J; Mittendorf T; Raspe H
    J Crohns Colitis; 2013 Jun; 7(5):355-68. PubMed ID: 22503168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation.
    Park KT; Ehrlich OG; Allen JI; Meadows P; Szigethy EM; Henrichsen K; Kim SC; Lawton RC; Murphy SM; Regueiro M; Rubin DT; Engel-Nitz NM; Heller CA
    Inflamm Bowel Dis; 2020 Jan; 26(1):1-10. PubMed ID: 31112238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Treatment Patterns and Healthcare Resource Use for Ulcerative Colitis and Crohn's Disease in Italy.
    Dovizio M; Hartz S; Buzzoni C; Redondo I; Nedeljkovic Protic M; Birra D; Perrone V; Veronesi C; Degli Esposti L; Armuzzi A
    Adv Ther; 2024 Jun; 41(6):2282-2298. PubMed ID: 38619721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare resource utilization and treatment costs of Finnish chronic inflammatory bowel disease patients treated with infliximab
    Ylisaukko-Oja T; Torvinen S; Ventola H; Schmidt S; Herrala S; Kononoff J; Voutilainen M
    Scand J Gastroenterol; 2019 Jun; 54(6):726-732. PubMed ID: 31203693
    [No Abstract]   [Full Text] [Related]  

  • 8. Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research Database.
    McAuliffe ME; Lanes S; Leach T; Parikh A; Faich G; Porter J; Holick C; Esposito D; Zhao Y; Fox I
    Curr Med Res Opin; 2015; 31(9):1655-64. PubMed ID: 26135040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study.
    Burisch J; Vardi H; Schwartz D; Friger M; Kiudelis G; Kupčinskas J; Fumery M; Gower-Rousseau C; Lakatos L; Lakatos PL; D'Incà R; Sartini A; Valpiani D; Giannotta M; Arebi N; Duricova D; Bortlik M; Chetcuti Zammit S; Ellul P; Pedersen N; Kjeldsen J; Midjord JMM; Nielsen KR; Winther Andersen K; Andersen V; Katsanos KH; Christodoulou DK; Domislovic V; Krznaric Z; Sebastian S; Oksanen P; Collin P; Barros L; Magro F; Salupere R; Kievit HAL; Goldis A; Kaimakliotis IP; Dahlerup JF; Eriksson C; Halfvarson J; Fernandez A; Hernandez V; Turcan S; Belousova E; Langholz E; Munkholm P; Odes S;
    Lancet Gastroenterol Hepatol; 2020 May; 5(5):454-464. PubMed ID: 32061322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics.
    Mandel MD; Bálint A; Lovász BD; Gulácsi L; Strbák B; Golovics PA; Farkas K; Kürti Z; Szilágyi BK; Mohás A; Molnár T; Lakatos PL
    Eur J Health Econ; 2014 May; 15 Suppl 1():S121-8. PubMed ID: 24832845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease.
    Rubin DT; Mody R; Davis KL; Wang CC
    Aliment Pharmacol Ther; 2014 May; 39(10):1143-55. PubMed ID: 24697826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smoking is Associated with Higher Disease-related Costs and Lower Health-related Quality of Life in Inflammatory Bowel Disease.
    Severs M; Mangen MJ; van der Valk ME; Fidder HH; Dijkstra G; van der Have M; van Bodegraven AA; de Jong DJ; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; van de Meeberg PC; Mahmmod N; Ponsioen CY; Vermeijden JR; van der Meulen-de Jong AE; Pierik M; Siersema PD; Oldenburg B;
    J Crohns Colitis; 2017 Mar; 11(3):342-352. PubMed ID: 27647859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.
    van der Valk ME; Mangen MJ; Leenders M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; Pierik M; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; Mahmmod N; van de Meeberg PC; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk CJ; Vermeijden JR; Siersema PD; van Oijen MG; Oldenburg B;
    Gut; 2014 Jan; 63(1):72-9. PubMed ID: 23135759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults.
    Kappelman MD; Rifas-Shiman SL; Porter CQ; Ollendorf DA; Sandler RS; Galanko JA; Finkelstein JA
    Gastroenterology; 2008 Dec; 135(6):1907-13. PubMed ID: 18854185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey.
    Gunnarsson C; Chen J; Rizzo JA; Ladapo JA; Lofland JH
    Dig Dis Sci; 2012 Dec; 57(12):3080-91. PubMed ID: 22790905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-drug costs associated with outpatient infliximab administration in pediatric inflammatory bowel disease.
    Wu M; Sin A; Nishioka F; Park KT
    Inflamm Bowel Dis; 2013 Jun; 19(7):1514-7. PubMed ID: 23567783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Evolution of Health Care Utilisation and Costs for Inflammatory Bowel Disease Over Ten Years.
    Pillai N; Dusheiko M; Maillard MH; Rogler G; Brüngger B; Bähler C; Pittet VEH;
    J Crohns Colitis; 2019 May; 13(6):744-754. PubMed ID: 30916775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost Burden of Crohn's Disease and Ulcerative Colitis in the 10-Year Period Before Diagnosis-A Danish Register-Based Study From 2003-2015.
    Vadstrup K; Alulis S; Borsi A; Gustafsson N; Nielsen A; Wennerström ECM; Jørgensen TR; Qvist N; Munkholm P
    Inflamm Bowel Dis; 2020 Aug; 26(9):1377-1382. PubMed ID: 31693731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health care costs associated with Australian tertiary inflammatory bowel disease care.
    Jackson B; Con D; Ma R; Gorelik A; Liew D; De Cruz P
    Scand J Gastroenterol; 2017 Aug; 52(8):851-856. PubMed ID: 28509590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease.
    Spekhorst LM; Oldenburg B; van Bodegraven AA; de Jong DJ; Imhann F; van der Meulen-de Jong AE; Pierik MJ; van der Woude JC; Dijkstra G; D'Haens G; Löwenberg M; Weersma RK; Festen EAM;
    World J Gastroenterol; 2017 Dec; 23(46):8182-8192. PubMed ID: 29290654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.